GlassScriptPhysician profile
Jatin B Daas
NPI 1326141722
$3,059.22
in general payments reported to CMS, 2019-2025
31 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $86.41 · 2021: $60.54 · 2022: $802 · 2023: $531 · 2024: $288 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.62 |
| Education | $131.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $279.19 | 2019-2023 | Proclaim |
| Inari Medical, INC. | $242.75 | 2022 | |
| Novo Nordisk INC | $221.39 | 2019-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $168.37 | 2022-2024 | Eluvia, Watchman Flx |
| Amgen INC. | $164.59 | 2025 | Krystexxa |
| Pfizer INC. | $139.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $126.68 | 2022-2025 | Trelegy Ellipta |
| Biosense Webster, INC. | $123.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.80 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $113.77 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $74.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.68 | 2022-2023 | |
| Astellas Pharma US INC | $74.21 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $60.34 | 2019-2023 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $54.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.71 | 2019-2020 | |
| Abbvie INC. | $40.85 | 2023-2024 | Viberzi, Linzess |
| Topcon Healthcare Solutions, INC. | $32.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.55 | 2024 | Gattex |
| Gilead Sciences, INC. | $29.15 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.80 | 2019-2020 | |
| Grifols USA, LLC | $22.85 | 2019 | |
| Teleflex LLC | $22.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2019 | |
| Medtronic USA, INC. | $17.32 | 2019 | |
| Exact Sciences Corporation | $16.52 | 2023 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $15.18 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.22 | 2022 | |
| Allergan, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatin Daas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.